Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | MST1R over exp |
| Gene Variant Detail | |
| Relevant Treatment Approaches | RON Inhibitor IMC-41A10 Narnatumab Zt/f2 Zt/g4 Zt/g4-DM1 |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| MST1R over exp | colon cancer | predicted - sensitive | IMC-41A10 RON Inhibitor | IMC-41A10 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, IMC-41A10 inhibited MST1R (RON) downstream signaling and migration of colon cancer cells in culture, and reduced tumor growth in MST1R-positive colorectal cancer xenograft models (PMID: 16982759). | 16982759 |
| MST1R over exp | urinary bladder cancer | decreased response | Epirubicin | Preclinical - Cell culture | Actionable | In a preclinical study, MST1R (RON) over expression resulted in decreased sensitivity to Ellence (epirubicin) in bladder cancer cells under hypoxia in culture, resulting in increased cell survival (PMID: 26772202). | 26772202 |